General Information of Drug (ID: DMKFE6X)

Drug Name
IN1535 Drug Info
Synonyms 220792-57-4; CTK8F1119; K00613a; ZINC00582597; NCGC00390411-01; RT-011271
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9549304
TTD Drug ID
DMKFE6X

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [2]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [2]
P-276 DMMJUHD Breast cancer 2C60-2C65 Phase 2 [4]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [5]
AG-024322 DMY4WVK Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
PHA-793887 DM2Y4FG Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
Oxazolyl methylthiothiazole derivative 1 DMZM6FW N. A. N. A. Patented [7]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [8]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase 1 (CDK1) TTH6V3D CDK1_HUMAN Binder [1]

References

1 M-phase regulation of the recruitment of mRNAs onto polysomes using the CDK1/cyclin B inhibitor aminopurvalanol. Biochem Biophys Res Commun. 2003 Jul 11;306(4):880-6.
2 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
3 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
4 P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
5 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
6 A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
7 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
8 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
9 Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.